Treatment of hepatitis C with interferon-α and ribavirine in a patient with long-term clozapine treatment [2]

Psychosomatics

Volumn 49, Issue 1, 2008, Pages 86-88

  Liukkonen, Timo ^a   Sorjonen, Mirja ^b   Jokelainen, Jari ^b   Timonen, Markku ^b  

^a Savonlinna Central Hospital   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL; BISOPROLOL FUMARATE; CLOZAPINE; LAMOTRIGINE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; LETTER; LEUKOCYTE COUNT; MALE; NEUTROPHIL COUNT; PSYCHOSIS; SIDE EFFECT;

EID: 37549042819     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.49.1.86-a     Document Type: Letter

References (6)

1. Rosenberg SD, Goodman LA, Osher FC, et al: Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 2001; 91:31-37
2. Casato M, Pucillo LP, Leoni M, et al: Granulocytopenia after combined therapy with interferon with angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity. Am J Med 1995; 99:386-391
3. Gerson S, Lieberman JA, Friedenberg WR, et al: Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet 1991; 338:262-263
4. Hoffman RM, Ott S, Parhofer KG, et al: Interferon-α-induced agranulocytosis in a patient on long-term clozapine therapy. J Hepatol 1998; 29:170
5. Zung S, Hong M, Forte G: Agranulocytosis induced by interferon-α and ribavirin in a patient with schizophrenia using clozapine. Rev Bras Psiquiatr 2006; 28:80-85
6. Dalgard O, Mangia A: Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infections. Drugs 2006; 66:1807-1815